Cargando…

Hydroxychloroquine (HCQ) decreases the benefit of anti-PD-1 immune checkpoint blockade in tumor immunotherapy

Immunotherapy using checkpoint blockade (ICB) with antibodies such as anti-PD-1 has revolutionised the treatment of many cancers. Despite its use to treat COVID-19 patients and autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis, the effect of hydroxychloroquine (HCQ) o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Krueger, Janna, Santinon, Francois, Kazanova, Alexandra, Issa, Mark E., Larrivee, Bruno, Kremer, Richard, Milhalcioiu, Catalin, Rudd, Christopher E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8238207/ https://www.ncbi.nlm.nih.gov/pubmed/34181666 http://dx.doi.org/10.1371/journal.pone.0251731

Ejemplares similares

Clarifying misbeliefs about hydroxychloroquine (HCQ): developing the HCQ benefits versus harm decision aid (HCQ-SAFE) per low health literacy standards
por: Garg, Shivani, et al.
Publicado: (2023)

Hydroxychloroquine (HCQ): real treatment or false hope?
por: El Bakkouri, Karim
Publicado: (2021)

Direct AKT activation in tumor-infiltrating lymphocytes markedly increases interferon-γ (IFN-γ) for the regression of tumors resistant to PD-1 checkpoint blockade
por: Santinon, François, et al.
Publicado: (2022)

The efficacy and safety of hydroxychloroquine (HCQ) in treatment of COVID19 –a systematic review and meta-analysis
por: Choudhuri, Anirban Hom, et al.
Publicado: (2021)

Programmed cell death 1 ligand (PD-L1) on T cells generates Treg suppression from memory
por: Kazanova, Alexandra, et al.
Publicado: (2021)

The ‘myth of Hydroxychloroquine (HCQ) as post-exposure prophylaxis (PEP) for the prevention of COVID-19’ is far from reality
por: Dhibar, Deba Prasad, et al.
Publicado: (2023)

Molecular Insights into the MAPK Cascade during Viral Infection: Potential Crosstalk between HCQ and HCQ Analogues
por: Mohanta, Tapan Kumar, et al.
Publicado: (2020)

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
por: Wang, Xin, et al.
Publicado: (2019)

Quantitative Fundus Autofluorescence in HCQ Retinopathy
por: Greenstein, Vivienne C., et al.
Publicado: (2020)

A Study on Hydroxychloroquine (HCQ) as prophylaxis among Health care worker (HCW) for SARS -Co V-2 infection
por: Ghosh, Anindya, et al.
Publicado: (2021)

Pharmacist's perspective on HCQ treatment of COVID‐19
por: Wang, Ya‐Ling, et al.
Publicado: (2020)

Immunotherapy of alveolar echinococcosis via PD‐1/PD‐L1 immune checkpoint blockade in mice
por: Wang, Junhua, et al.
Publicado: (2018)

Hydroxychloroquine for pre-exposure prophylaxis of COVID-19 in health care workers: a randomized, multicenter, placebo-controlled trial Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine (HERO-HCQ)
por: Naggie, Susanna, et al.
Publicado: (2023)

β-Glucan Combined With PD-1/PD-L1 Checkpoint Blockade for Immunotherapy in Patients With Advanced Cancer
por: Wang, Mengjie, et al.
Publicado: (2022)

HCQ induced QT prolongation- Primum non nocere
por: Mahendran, A.J., et al.
Publicado: (2020)

Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer
por: Wu, Bogang, et al.
Publicado: (2018)

Seeing is believing: anti-PD-1/PD-L1 monoclonal antibodies in action for checkpoint blockade tumor immunotherapy
por: Tan, Shuguang, et al.
Publicado: (2016)

Immune-Checkpoint Blockade and Active Immunotherapy for Glioma
por: Ahn, Brian J., et al.
Publicado: (2013)

Epigenetic checkpoint blockade: new booster for immunotherapy
por: Wang, Ziqiao, et al.
Publicado: (2021)

HCQ use not protective against SARS-CoV-2
por: Onuora, Sarah
Publicado: (2020)

An update on immunotherapy with PD-1 and PD-L1 blockade
por: Koh, Sung Ae
Publicado: (2021)

Application of PD-1 Blockade in Cancer Immunotherapy
por: Wu, Xiaomo, et al.
Publicado: (2019)

A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints
por: Li, Yongshu, et al.
Publicado: (2016)

The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition
por: Kreidieh, Firas Y., et al.
Publicado: (2023)

Immune checkpoint expression and relationships to anti-PD-L1 immune checkpoint blockade cancer immunotherapy efficacy in aged versus young mice
por: Garcia, Myrna G., et al.
Publicado: (2022)

Noninvasive imaging of the PD-1:PD-L1 immune checkpoint: Embracing nuclear medicine for the benefit of personalized immunotherapy
por: Broos, Katrijn, et al.
Publicado: (2018)

Human Cancer Immunotherapy with PD-1/PD-L1 Blockade
por: Zheng, Peilin, et al.
Publicado: (2015)

Targeted Glucose or Glutamine Metabolic Therapy Combined With PD-1/PD-L1 Checkpoint Blockade Immunotherapy for the Treatment of Tumors - Mechanisms and Strategies
por: Ma, Guofeng, et al.
Publicado: (2021)

Can HCQ Be Considered a “Safe Weapon” for COVID-19 in the Indian Population?
por: Thangaraju, Pugazhenthan, et al.
Publicado: (2020)

A Threshold Model for T-Cell Activation in the Era of Checkpoint Blockade Immunotherapy
por: Guram, Kripa, et al.
Publicado: (2019)

Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies
por: Ilcus, Cristina, et al.
Publicado: (2017)

Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy
por: Lee, Ju Yeon, et al.
Publicado: (2016)

A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy
por: Du, Xuexiang, et al.
Publicado: (2018)

Further Advances in Cancer Immunotherapy: Going Beyond Checkpoint Blockade
por: Wilkinson, Robert W., et al.
Publicado: (2018)

Lessons learned from the blockade of immune checkpoints in cancer immunotherapy
por: Li, Xiaolei, et al.
Publicado: (2018)

PRKDC: new biomarker and drug target for checkpoint blockade immunotherapy
por: Tan, Kien Thiam, et al.
Publicado: (2020)

Microbial synthesis of Prussian blue for potentiating checkpoint blockade immunotherapy
por: Wang, Dongdong, et al.
Publicado: (2023)

Checkpoint Blockade Cancer Immunotherapy Targets Tumour-Specific Mutant Antigens
por: Gubin, Matthew M., et al.
Publicado: (2014)

T-cell response to checkpoint blockade immunotherapies: from fundamental mechanisms to treatment signatures
por: Elliot, Thomas A.E., et al.
Publicado: (2023)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
por: Liu, Jinhua, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_du94k2o6040hf3gc9n2r3voo8k